Next-generation CRISPR screens to fast-forward drug discovery

Our Technology

At Myllia, we perform functional genomics at scale in advanced cellular models to map the impact of thousands of genetic perturbations at single-cell resolution – a new paradigm to nominate the best possible targets for your drug discovery campaign. Our technology platform enables tailor-made CRISPR screens:


Pooled CRISPR screens accelerate drug target discovery across many therapeutic areas and help unravel gene regulatory networks in cancer cells and primary human T cells. We utilize CRISPR KO, CRISPRi and CRISPRa technologies combined with multiple high-throughput read-outs for various applications:

Drug screens for target identification and validation

Mode of action (MoA) analysis

Identification of disease-associated gene function and immune pathways

Genetic screening 
for phenotypes of 
primary T cells

Genetic screening for primary T cell phenotypes

Genetic perturbation screens at single-cell resolution revolutionize the way we identify novel drug targets and gene regulatory networks involved in oncology and autoimmune disease.